Advocating for a world where intellectual
property law serves the public interest.
Last week the U.S. tabled additional text on intellectual property at the Trans Pacific Partnership negotiating round in Chicago. The text is confidential, but trade officials told reporters that it includes TRIPS-Plus measures affecting access to medicines such as”stronger patent linkage, patent term extension and data exclusivity provisions.” The inclusion of these provisions amounts to […]
In a speech to the Royal Television Society, UK Culture Secretary Jeremy Hunt has suggested that the British government may “look at legislative solutions” to crack down on infringing content online. His specific suggestions: “A cross-industry body, perhaps modeled on the Internet Watch Foundation, to be charged with identifying infringing websites against which action could […]
IP-Enforcement Roundup – September 12, 2011 Washington Declaration on Intellectual Property and the Public Interest Intellectual property and information policy experts from around the world have released the Washington Declaration on Intellectual Property and the Public Interest. Citing an “unprecedented expansion of the concentrated legal authority exercised by intellectual property rights holders” through recent trade […]
The statement of the administration today continues its practice of actively thwarting the release of meaningful information about its positions in closed door international law making. The statement says little about what the administration’s actual trade policy on medicines issues is or what justifies it. It does not explain any of the positions it has […]
Here is some of what we learned at the TPP negotiation in Chicago this week. Transparency will be worse than ACTA. In response to the repeated calls in civil society and academic presentations for TPP negotiators to increase transparency in the process, including through ongoing releases of negotiating text, USTR officials signaled that the process […]
On September 6, a Division Branch of the Supreme Court of India was going to hear Novartis’ challenge to the Appellate Decision that prevented it from patenting imatinib messylate, but Judge Dalveer Bhandari recused himself and sent the matter to another branch. Novartis’ patent application was rejected because the drug was found to be a […]
Posts by Category
- Video
- User Rights Network
- US Domestic Policies
- US Domestic Legislation
- Transparency
- Trade Agreements
- Takedown
- Trade Disputes
- Trademark
- Round-up
- Regional Fora
- Surveys and Data
- Positive Agenda
- Patent Pledges
- Open
- News
- Multilateral Fora
- Limitations and Exceptions
- IP & Research
- IP and Human Rights
- Industry Initiatives
- Flagged
- Fair Use
- Events
- Empirical Research
- Document Library
- Coronavirus
- Brazil
- Blog
- Bilateral Trade Pressures
- Artificial Intelligence
- AI
- Africa Group Work Plan Proposal
- Africa: Copyright & Public Interest
- Access to Medicine
- Academic Resources